Darrell H. Carney, PhD, President and CEO, has a proven record as a successful academic scientist and over 15 years of experience in biopharmaceutical corporate management. His former tissue repair company, Chrysalis BioTechnology, Inc., raised ~$17 million in investment, strategic partner payments, and NIH funding and was awarded a prestigious Frost and Sullivan Technology Innovation Award and Deloitte & Touche Fast 50 and Fast 500 awards for being among the fastest growing companies in Texas and the US. After completing Phase 2 human clinical trials for two indications, the company was acquired, providing investors a successful exit. He subsequently founded RADIX Therapeutics to develop a medicinal countermeasure for nuclear radiation, orchestrated the acquisition of Chrysalin® assets, and morphed RADIX Therapeutics into Chrysalis BioTherapeutics to continue efforts to mitigate effects of radiation and capitalize on the regenerative properties of Chrysalin®. Thus, he has an established record of building companies and generating revenue for investors through drug development.
Clarice Motter, Interim CFO, is a licensed CPA with more than 20 years’ experience as an accountant and administrative professional. Her experience in public and privately owned companies includes mergers, acquisitions, and public offerings. She has recently worked with a number of early-stage companies bringing them into fiscal compliance and playing a key role in raising funding through public and private sources.
Gerald M Fuller, PhD, Vice President of Technology, is a Professor Emeritus, Department of Cell Biology at the University of Alabama Medical School with expertise in molecular biology, progenitor cell biology, and the biology of vascular pericytes. Gerry was one of the first scientists to discover IL-6 and its involvement in stimulating hepatocytes. Gerry has been a scientific consultant with Chrysalis BioTechnology, OrthoLogic, and Merck and currently directs a team of scientists working to better understand the molecular mechanisms by which Chrysalin® targets progenitor cells to protect and regenerate tissues.
Laurie Sower, PhD, Vice President of Research, Director Regulated Laboratory Studies, has over 15 years in directing laboratory operations, quality data system management, and prior experience with Chrysalin®. Her prior research at the University of Texas Medical Branch demonstrated a unique TP508 (Chrysalin®) receptor-mediated signaling cascade involved in tissue repair. Laurie is the Principle Investigator (PI/PD) on the company’s SBIR Phase 2 grants and directs all Non-Clinical Regulated Studies for Chrysalis BioTherapeutics.
Deb Koeneman, MS, Director of Regulatory Affairs, has a 15 year history with Chrysalin® regulatory development. She has expertise in pharmaceutical regulatory strategy from early stage preclinical and CMC programs to successful FDA submissions. Deb currently manages the Chrysalis BioTherapeutics open IND for Chrysalin® treatment of diabetic foot ulcers and leads regulatory strategy for Chrysalin® use in mitigating effects of acute nuclear radiation exposure (Pre-IND meeting August 2013) and for use in combination with radiation therapy to protect normal tissues.
Andrew Tang, MS, MBA, Formulation and CMC Consultant, has managed GMP CMO and CRO’s in the manufacturing of several drug products and has had over 10 years of experience with former companies in the development and formulation of Chrysalin® for topical application and local injection delivery. Andrew is working with GMP manufactures on a new formulation of Chrysalin® for use as an injectable drug that can be delivered clinically and for “in field” emergency use to mitigate effects of radiation exposure.
Michael C. Blaney, Corporate Legal Counsel, has 25 years of corporate law practice, formerly with Winstead and Vinson & Elkins. Mike established Blaney & Associates, PC to work more closely with early stage biotech companies in the Houston area. Mike assisted Dr. Carney during the founding of his first biotech start up company a number of years ago and began representing Chrysalis BioTherapeutics in 2012.
James T. Ryaby, PhD, Director, is currently Chief Scientific Officer of Orthofix International (NASDAQ: OFIX). Jim was the former Senior Vice President and Chief Scientific Officer at Capstone Therapeutics where he managed external biodiscovery collaborations with scientists around the world and clinical development of Chrysalin® for potential use in fracture and cartilage repair, spine fusion, and cardiovascular indications. Subsequently, Jim served as Vice President of Research at Mesoblast LTD., a company focusing on developing clinical use of mesenchymal stem cell therapies. Jim has 27 years of experience in pharmaceutical and medical device development, design and management of clinical trials, and moving products through the FDA and into clinical use. Jim has played a key role as part of the start-up team in recognizing the potential of Chrysalin® in regenerative medicine.